BiomX to Present Data From Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients With Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)

Abstract selected as a "Top Poster", ranking it among the 1-2% of top-rated abstracts in the category submitted and accepted at ECCMID 2024CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 23, 2024 (GL

GlobeNewswireApr 23 20:00

HC Wainwright & Co. : The BioMX (PHGE.US) rating was confirmed and adjusted from buy to buy, with a target price of $2.00.

HC Wainwright & Co. : The BioMX (PHGE.US) rating was confirmed and adjusted from buy to buy, with a target price of $2.00.

Zhitong FinanceApr 22 18:40

BiomX's BX211 Phage Therapy: A Revolutionary Approach to Diabetic Foot Osteomyelitis Treatment

TipRanksApr 22 18:16

Press Release: BiomX Announces the Appointment of Susan Blum to Its Board of Directors

BiomX Announces the Appointment of Susan Blum to its Board of Directors CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "C

Dow JonesApr 18 20:00

BiomX Board Governance Structure and Bylaws Updated

TipRanksApr 16 05:32

Biomx Inc. at a Crossroads: Shareholder Approval Required for Convertible Securities Amid Liquidity Concerns

TipRanksApr 5 14:00